FIELD: medicine.
SUBSTANCE: invention relates to medicine and the chemical and pharmaceutical industry and relates to the use of diumancal – 7,7'-ethylenedioxy-2H-1-dibenzopyran-2,2'-dione.
EFFECT: invention can be used as an anticoagulant of indirect action to replace a known drug of warfarin in clinical practice.
1 cl, 4 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIARRHYTHMIC DRUG BASED ON HYBRID MOLECULES OF AMLODIPINE WITH (7-METHOXICUMARIN-4-YL)ACETIC ACID | 2018 |
|
RU2678969C1 |
| ANTIARRHYTHMIC MEDICATION BASED ON 4-METHYL-7,7'-ETHYLENEDIOXY-2H-1-DIBENZOPYRAN-2,2'-DIONE | 2010 |
|
RU2427368C1 |
| HYBRID COUMARINS WITH INDIRECT ANTICOAGULANT ACTION | 2018 |
|
RU2672062C1 |
| MEDICAMENT WITH PROLONGED ANTI-CALCIUM ACTIVITY IN THE FORM OF 1/10% INTRAVENOUS SOLUTION | 2004 |
|
RU2255728C1 |
| ANTICOAGULANT AGENT OF INDIRECTLY ACTION BASED ON NEW HYBRID MOLECULE OF WARFARIN WITH ESSENTIAL ACID | 2018 |
|
RU2677647C1 |
| DERIVATIVES OF 2-H-1-BENZOPYRANE-2-ONE ELICITING ANTI-CALCIUM ACTIVITY | 2003 |
|
RU2242471C1 |
| IMMUNOMODULATORY AND ANTIVIRAL AGENT BASED ON (2-((COUMARIN-7-YL)OXY)ETHYL) 3-HYDROXY-20(29)-LUPEN-28-OATE | 2018 |
|
RU2686743C1 |
| AGENT FOR TREATMENT OF PATIENT WITH HEART ISCHEMIC DISEASE | 1998 |
|
RU2155036C2 |
| METHOD OF PREPARING DIUMANCAL-FORTE TABLETS IN DOSE 0,01 G | 2000 |
|
RU2187303C2 |
| ANCARDIN-RETARD AS AGENT WITH PROLONGED ANTI-CALCIUM EFFECT | 2002 |
|
RU2219927C1 |
